利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.019 秒)

    TREATMENT INVOLVING CAR-ENGINEERED T CELLS AND CYTOKINES
    6.
    发明公开
    TREATMENT INVOLVING CAR-ENGINEERED T CELLS AND CYTOKINES 审中-公开

    公开(公告)号：EP4414033A3

    公开(公告)日：2024-10-30

    申请号：EP24170617.5

    申请日：2020-02-06

    申请人： BIONTECH CELL & GENE THERAPIES GMBH

    发明人： SAHIN, Ugur ,  OEHM, Petra ,  RENGSTL, Benjamin ,  REINHARD, Katharina

    IPC分类号： A61K38/20 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00

    摘要： The present disclosure relates to methods and agents for enhancing the effect of T cells engineered to express chimeric antigen receptors (CARs). These methods and agents are, in particular, useful for the treatment of diseases characterized by diseased cells expressing an antigen the CAR is directed to.
    Specifically, the present disclosure relates to methods comprising providing to a subject T cells genetically modified to express a chimeric antigen receptor (CAR) and administering to the subject IL2 or a polynucleotide encoding IL2. The methods of the disclosure may comprise administering IL2 or a polynucleotide encoding IL2 and a further cytokine or a polynucleotide encoding a further cytokine, wherein the further cytokine may be IL7 or IL21. The T cells genetically modified to express a CAR may be provided to the subject by administering the T cells genetically modified to express a CAR or by generating the T cells genetically modified to express a CAR in the subject. The methods of the disclosure may further comprise administering to the subject an antigen or a variant thereof, or a polynucleotide encoding an antigen or a variant thereof, wherein the T cell genetically modified to express a CAR are targeted to the antigen. In one particularly preferred embodiment, the polynucleotides administered according to the present disclosure are RNA.